Derma Sciences To Hold Conference Call On November 12 To Discuss Data Monitoring Committee Pre-Specified Interim Analysis Of The Aclerastide Phase 3 Trials
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, will issue a news release at 7:30 a.m. Eastern time on November 12 announcing the findings of the Data Monitoring Committee planned, pre-specified interim analysis of the aclerastide Phase 3 clinical trials for the closure of diabetic foot ulcers. A conference call will be held to discuss the findings beginning at 8:30 a.m. Eastern time that same day.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.